Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2No longer available 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Thoracic 3

Conditions

Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 1Carcinoma, Bronchogenic 1

Interventions

Carboplatin 542Pemetrexed 392pembrolizumab 372Cisplatin 356Paclitaxel 285Docetaxel 240Gemcitabine 168Nivolumab 158Erlotinib Hydrochloride 147Bevacizumab 114atezolizumab 104osimertinib 99durvalumab 92Etoposide 90Gefitinib 68130-nm albumin-bound paclitaxel 65Cetuximab 64Ipilimumab 60Drug Therapy 51Topotecan 48Injections 44Afatinib 41tislelizumab 40Cyclophosphamide 39Albumin-Bound Paclitaxel 37Vinorelbine 36Crizotinib 34cemiplimab 31icotinib 26Radiotherapy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × belagenpumatucel L × Thoracic × Clear all
NCT00676507 2015-05-08

STOP

NovaRx Corporation

Phase 3 Completed
532 enrolled
Thoracic

Lung Neoplasms

NCT01279798 2011-03-01

Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)

NovaRx Corporation

No longer available
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01058785 2010-07-29

Phase II Study of Lucanixâ„¢ in Patients With Stages II-IV Non-Small Cell Lung Cancer

NovaRx Corporation

Phase 2 Completed
75 enrolled
Thoracic

Carcinoma, Bronchogenic, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡